Ball-and-stick model of the toceranib molecule
Clinical data
Trade names Palladia
AHFS/ International Drug Names
Routes of
ATCvet code QL01XE91 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 77%
Protein binding 91%-93%
Biological half-life 16 h
CAS Number 356068-94-5
PubChem (CID) 8034466
ChemSpider 4486268
UNII 59L7Y0530C YesY
Chemical and physical data
Formula C22H25FN4O2
Molar mass 396.46 g/mol
494.46 g/mol (phosphate)
3D model (Jmol) Interactive image

Toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment[1] of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science), toceranib is the only dog-specific anti-cancer drug[2] approved by the U.S. Food and Drug Administration.[3] It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654,[4] a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.


This article is issued from Wikipedia - version of the 9/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.